Target product profiles
Report – Diagnostics for neglected tropical diseases: defining the best tools through target product profiles
PATH has created target product profiles to engage product developers as part of its commitment to accelerating development of new diagnostics for neglected tropical diseases (NTDs). PATH examined existing diagnostic tests for NTDs and assessed their sufficiency for the different stages in preventive chemotherapy-based disease control and elimination, corresponding to the diagnostic test use cases. Current diagnostics for soil-transmitted helminthiasis (STH), schistosomiasis, and trachoma are generally sufficient for the intended use cases of mapping and impact monitoring. However, significant gaps exist in the availability of diagnostic tools to support decision-making for stopping mass drug administration (MDA) and conducting post-MDA surveillance.
To catalyze efforts to reach the World Health Organization’s NTD goals by 2020, PATH has focused on accelerating the development of new diagnostics for use at later control stages, where fewer tools currently exist. Resulting target product profiles for various platforms developed by PATH can be found below.
Target product profiles – MDA stopping decision use case
- General platforms: STH | Schistosomiasis
- Lateral flow test detecting antigen: STH | Schistosomiasis | Trachoma
- Field-deployable nucleic acid amplification test (NAAT): STH | Schistosomiasis | Trachoma
Target product profiles – Post-MDA surveillance use case
Tala de los Santos, Project Leader
This project was supported by grants from the Bill & Melinda Gates Foundation and the Department for International Development.